Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Onconova Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: ONTX), will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. An on-demand corporate overview by President & CEO Steven Fruchtman will be available starting November 22, 2021, at 10:00 a.m. ET. Registered attendees can access the presentation until December 2, 2021. Additionally, Onconova will engage in 1x1 meetings from November 30 to December 2, 2021, requested exclusively through Piper Sandler.
Onconova focuses on novel cancer therapies, including narazaciclib and rigosertib.
- None.
- None.
NEWTOWN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 29, 2021 through December 2, 2021.
A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-demand beginning today at 10:00 a.m. ET. The presentation can be viewed via the Piper Sandler presentation library on the conference site through December 2, 2021 for all registered attendees, and on the “Corporate Events and Presentations” section of the Onconova website.
The Company will also be participating in 1x1 meetings November 30, 2021 through December 2, 2021. Meetings can be requested exclusively via Piper Sandler.
About Onconova Therapeutics
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.
Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.
For more information, please visit www.onconova.com.
Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:
Bruce Mackle
LifeSci Advisors
929-469-3859
bmackle@lifesciadvisors.com
FAQ
What event will Onconova Therapeutics participate in?
Who will present Onconova's corporate overview?
When will Onconova's corporate overview be available for viewing?
How can attendees access Onconova's presentation?
What are Onconova's main product candidates?
